Good news, everyone. The system is working exactly as designed.
Senator Tommy Tuberville, Republican of Alabama and sitting member of the Senate Committee on Health, Education, Labor, and Pensions — a committee with, and we cannot stress this enough, direct oversight relevance to the pharmaceutical industry — sold somewhere between $15,001 and $50,000 worth of Pfizer stock on June 8th. We know this because he disclosed it on July 16th, which is 38 days later, which is the law, which is fine, which is all fine.
The amount is listed as a range because the STOCK Act, in a moment of inspired legislative craftsmanship, does not require members of Congress to tell you the actual number. A range. Like a weather forecast. There's a 30% chance this senator sold $49,000 in pharma stock while overseeing pharma policy.
Pfizer, for those keeping score at home, makes drugs. The Health, Education, Labor, and Pensions Committee oversees, among other things, drugs. We are not saying anything. We are simply reading the disclosure out loud in a room with adequate lighting.
The chart is all that matters. The rest of this is just vibes and a 38-day filing window.
— Phil McCandlestick, still not a financial advisor, still not surprised
Leave a Comment